Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PTOV1 antisense RNA 1 (non-protein coding) (PTOV1-AS1)
- Target
- PTOV1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-protein coding RNA
01
Overview
PTOV1 antisense RNA 1 (PTOV1-AS1) is a long non-coding RNA transcribed antisense to the PTOV1 gene, mainly expressed in the cytoplasm of tumor cells and acting as a molecular decoy for microRNAs such as miR-1207-5p and miR-149-5p. Through this mechanism, PTOV1-AS1 regulates key genes associated with tumor proliferation, survival, and resistance to treatments— notably impacting heme oxygenase-1 (HO-1) and Wnt/β-catenin pathway activity. PTOV1-AS1 is upregulated in several malignancies, such as osteosarcoma, prostate cancer, and colorectal cancer, and is considered both a promising biomarker and a potential therapeutic target for cancer intervention.
- Other names
- PTOV1-AS1PTOV1 antisense RNA 1 (non-protein coding)NR_040037ENSG00000268006HGNC:44174
02
Mechanism of action
Modulates miRNA availability by acting as a molecular decoy, thereby affecting the post-transcriptional repression of target genes (e.g., HO-1 via miR-1207-5p, Wnt pathway via miR-149-5p). Regulates the expression of oncogenic and cytoprotective genes, impacting proliferation, survival, and drug resistance in tumor cells.
03
Biological functions
Post-transcriptional regulation of gene expressionmiRNA sponge/decoy (specifically for miR-1207-5p and miR-149-5p)Regulation of cell proliferation and clonogenicity in cancerModulation of heme oxygenase-1 (HO-1) expression via miRNA activityRegulation of Wnt/β-catenin signaling pathway in tumor biology
04
Disease associations
Cancer (osteosarcoma, prostate cancer, colorectal cancer, breast cancer, laryngeal squamous cell carcinoma, urothelial carcinoma, ovarian cancer)Tumor progression and metastasisResistance to chemotherapeutic agents (e.g., 5-fluorouracil in colorectal cancer)
05
Safety considerations
Therapeutic challenges include potential off-target effects due to widespread regulatory roles of lncRNAsDifficulties in delivering RNA-targeting therapies specifically to diseased tissuesOver-expression may contribute to chemoresistance, inhibiting efficacy of conventional drugs
06
Interacting drugs
5-Fluorouracil (5-FU): PTOV1-AS1 modulates sensitivity to 5-FU in colorectal cancer by affecting miRNA and Wnt/β-catenin signaling
1 more in the full profile.
07
Biomarkers
PTOV1-AS1 expression level (differentially expressed in various cancers, potential as a diagnostic/prognostic biomarker in osteosarcoma and other tumors)Acts as a biomarker candidate for patient stratification or therapeutic response monitoring in cancers where it is upregulated
Beyond the preview
Go deeper on PTOV1 antisense RNA 1 (non-protein coding) (PTOV1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTOV1 antisense RNA 1 (non-protein coding) (PTOV1-AS1).